Benny A G, Ockelford P A, Johns A S, Scott R H, Woodfield D G, Berry E W
Blood Products Laboratory, Auckland Regional Blood Centre, New Zealand.
J Clin Pathol. 1988 Sep;41(9):945-7. doi: 10.1136/jcp.41.9.945.
A standard lyophilised triple cryoprecipitate preparation, stabilised by the addition of Synthamin 17, was heat treated at 60 degrees C for 48 hours. The total protein content, factor VIII concentration, and factor VIII recovery were not affected by the heat treatment procedure. Heat treatment did not influence the reconstitution characteristics of the freeze dried preparation and there were no side effects during or after administration. The mean in vivo rise of factor VIII from infused heat treated triple cryoprecipitate was 2.5 (SD 0.9)%/unit/kg with a half life of 13.1 (3.1) hours. These results compare favourably with those obtained using non-heated triple cryoprecipitate. Cryoprecipitate can be heat treated without adversely influencing factor VIII recovery, and the ability to prepare a heat treated cryoprecipitate means that a small pool high yield factor VIII preparation can again be used in routine clinical practice.
一种添加了17种合成氨基酸稳定的标准冻干三联冷沉淀制剂,在60摄氏度下热处理48小时。总蛋白含量、凝血因子VIII浓度和凝血因子VIII回收率不受热处理程序的影响。热处理不影响冻干制剂的复溶特性,给药期间或给药后均无副作用。输注热处理后的三联冷沉淀后,凝血因子VIII的体内平均升高幅度为2.5(标准差0.9)%/单位/千克,半衰期为13.1(3.1)小时。这些结果与使用未加热的三联冷沉淀所获得的结果相比更具优势。冷沉淀可以进行热处理而不会对凝血因子VIII回收率产生不利影响,并且能够制备热处理冷沉淀意味着一种小库存高产率的凝血因子VIII制剂可以再次用于常规临床实践。